Clinical features of COVID‐19 patients with non‐alcoholic fatty liver disease

Clinical features of COVID‐19 patients with non‐alcoholic fatty liver disease

Background and Aims Previous studies reported that coronavirus disease 2019 (COVID‐19) was likely to result in liver injury. However, few studies investigated liver injury in COVID‐19 patients with chronic liver diseases. We described the clinical features in COVID‐19 patients with non‐alcoholic fat...

Full description

Saved in:
Bibliographic Details
Published in:Hepatology Communications 2020
Main Authors: Huang, Rui, Zhu, Li, Wang, Jian, Xue, Leyang, Liu, Longgen, Yan, Xuebing, Huang, Songping, Yang, Li, Yan, Xiaomin, Zhang, Biao, Xu, Tianmin, Li, Chunyang, Ji, Fang, Fang, Ming, Zhao, Yun, Cheng, Juan, Wang, Yinling, Zhao, Haiyan, Hong, Shuqin, Chen, Kang, Xiang‐an Zhao, Zou, Lei, Sang, Dawen, Shao, Huaping, Guan, Xinying, Chen, Xiaobing, Chen, Yuxin, Wei, Jie, Zhu, Chuanwu, Wu, Chao
Format: Web Resource
Language:eng
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and Aims Previous studies reported that coronavirus disease 2019 (COVID‐19) was likely to result in liver injury. However, few studies investigated liver injury in COVID‐19 patients with chronic liver diseases. We described the clinical features in COVID‐19 patients with non‐alcoholic fatty liver disease (NAFLD). Methods Confirmed COVID‐19 patients from hospitals in 10 cities of Jiangsu province, China were retrospectively included between January 18, 2020, and February 26, 2020. Hepatic Steatosis Index (HSI) was used to defined NAFLD. Results A total of 280 COVID‐19 patients were enrolled. Eighty‐six (30.7%) of 280 COVID‐19 patients were diagnosed as NAFLD by HSI. 100 (35.7%) patients presented abnormal liver function on admission. The median ALT levels (34.5 U/L vs. 23.0 U/L, P40 U/L) (40.7% vs. 10.8%, P